ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Mavrilimumab Biosimilar - Anti-CD116 Antibody - Low endotoxin, Azide free (A323573)

Recombinant human monoclonal antibody to CD116 for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Mavrilimumab Biosimilar - Anti-CD116 Antibody - Low endotoxin, Azide free
Description
Recombinant human monoclonal antibody to CD116.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Cynomolgus Macaque
Host
Human
Clonality
Monoclonal
Isotype
IgG4
Light Chains
lambda
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 143.2 kDa.
Purity
> 95% (by SDS-PAGE and SEC-HPLC).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
CDw116, CSF2R, CSF2RA, CSF2RY, GM-CSF-R-alpha, GMCSFR-alpha, GMR-alpha, Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Mavrilimumab Biosimilar - Anti-CD116 Antibody - Low endotoxin, Azide free (A323573)? Please let us know so that we can list the citation on this page.

Alternative products to Mavrilimumab Biosimilar - Anti-CD116 Antibody - Low endotoxin, Azide free (A323573)

Proteins predicted to interact with CD116

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.9% Relevancy Score
99.9% Relevancy Score
87.9% Relevancy Score
86.4% Relevancy Score
84.2% Relevancy Score
80.9% Relevancy Score
80.9% Relevancy Score
78.5% Relevancy Score